Trials / Completed
CompletedNCT06168929
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
Bioequivalence Study of 2 Sizes of SHR4640 Tablets in Healthy Subjects (Randomized, Open, Single Dose, Two Sequences, Two Cycles, Self-Crossover Control)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the pharmacokinetic, and safety of two sizes of SHR4640 tablets in healthy adults, to explore the bioequivalence between two sizes of SHR4640 tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4640 | SHR4640, 2.5mg\*4 - 10mg\*1 |
| DRUG | SHR4640 | SHR4640, 10mg\*1 - 2.5mg\*4 |
Timeline
- Start date
- 2023-12-13
- Primary completion
- 2024-01-13
- Completion
- 2024-01-13
- First posted
- 2023-12-13
- Last updated
- 2024-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06168929. Inclusion in this directory is not an endorsement.